EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Bayesian model to analyse the association of comorbidities with biosimilar treatment retention in a non-medical switch scenario in patients with inflammatory rheumatic musculoskeletal diseases

Imke Redeker iD, Stefan Moustakis, Styliani Tsiami, Xenofon Baraliakos iD, David Kiefer, Ioana Andreica, Björn Buehring, Jürgen Braun iD, Uta Kiltz iD

Arthritis Research & Therapy · 2024

DOI: 10.1186/s13075-024-03386-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Research & Therapy, 2024. Verfasst von Imke Redeker und 8 weiteren Autor:innen. Beteiligte Einrichtung: Ruhr-Universität Bochum, Bochum, Germany. Hauptthemen laut MEDLINE: Bayes Theorem, Biosimilar Pharmaceuticals, Antirheumatic Agents, Comorbidity. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: St. Elisabeth Gruppe GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To analyse clinical outcomes of a non-medical switch from originator adalimumab (ADA) to its ABP501 biosimilar (ABP) over 6 months in patients with inflammatory rheumatic musculoskeletal diseases (RMD) in relation to comorbidity as a risk factor for therapy discontinuation.

Methods

RMD patients switching from originator ADA to ABP were identified from a large routine database from October 2018 onwards. Documented clinical data at the time of non-medical switching (baseline), and at 3 and 6 months were collected. Comorbidities were represented by the Charlson Comorbidity Index (CCI) at baseline and patients were categorized based on CCI > 0. Differences in the ABP retention rate over 6 months between patients with CCI = 0 and patients with CCI > 0 were analysed using Bayesian exponential regression.

Results

A total of 111 patients with axial spondyloarthritis ( n = 68), rheumatoid arthritis ( n = 23) and psoriatic arthritis ( n = 15), were identified, 74.8% of whom had continued treatment with ABP after 6 months, while a smaller proportion had either switched to another ADA biosimilar (10.8%), switched back to originator ADA (7.2%), switched to a different biologic (3.6%), or dropped out (3.6%). At baseline, a CCI > 0 was found in 38% of patients. Cardiovascular comorbidities (40%) were most prevalent followed by diseases of the skin (33%), the gastrointestinal tract (20%) and the eye (20%). ABP treatment was continued after 6 months in 74% of patients with CCI = 0 and in 76% with CCI > 0. Bayesian analysis showed only a small difference (months) in the APB continuation rate between groups (estimate 0.0012, 95% credible interval (CrI) -0.0337 to 0.0361). Adjusting for age, sex, and disease subtype revealed somewhat shorter retention rates for patients with CCI > 0, but the distribution of the difference included 0 (estimate -0.0689, 95% CrI -0.2246 to 0.0234).

Conclusion

In a non-medical switch scenario of RMD patients, there was no evidence for a considerable difference in ABP retention rates over 6 months between comorbidity groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bayes TheoremBiosimilar PharmaceuticalsAntirheumatic AgentsComorbidityAdalimumabHumansFemaleMaleMiddle AgedAdultDrug SubstitutionRheumatic DiseasesAgedMusculoskeletal DiseasesTreatment Outcome

Stichwörter der Autor:innen

AdherenceBiosimilarsComorbidities

Substanzen

Biosimilar PharmaceuticalsAntirheumatic AgentsAdalimumab

Autor:innen und Institutionen

  • Ruhr-Universität Bochum, Bochum, Germany.
  • Rheumazentrum Ruhrgebiet, Ruhr-Universität Bochum, Claudiusstrasse 45, Herne, 44649, Germany.
  • Krankenhaus St. Josef, Wuppertal, Germany.
  • RVZ Steglitz, Berlin, Germany.
  • Ruhr-Universität Bochum, Bochum, Germany. uta.kiltz@elisabethgruppe.de.
  • Rheumazentrum Ruhrgebiet, Ruhr-Universität Bochum, Claudiusstrasse 45, Herne, 44649, Germany. uta.kiltz@elisabethgruppe.de.

ORCID-Profile: Imke Redeker, Xenofon Baraliakos, Jürgen Braun, Uta Kiltz

Förderung

  • St. Elisabeth Gruppe GmbH

Zitieren

APA

Redeker, I., Moustakis, S., Tsiami, S., Baraliakos, X., Kiefer, D., Andreica, I., Buehring, B., Braun, J., & Kiltz, U. (2024). A Bayesian model to analyse the association of comorbidities with biosimilar treatment retention in a non-medical switch scenario in patients with inflammatory rheumatic musculoskeletal diseases. Arthritis Research & Therapy. https://doi.org/10.1186/s13075-024-03386-7

Vancouver

Redeker I, Moustakis S, Tsiami S, Baraliakos X, Kiefer D, Andreica I, et al. A Bayesian model to analyse the association of comorbidities with biosimilar treatment retention in a non-medical switch scenario in patients with inflammatory rheumatic musculoskeletal diseases. Arthritis Research & Therapy. 2024. doi:10.1186/s13075-024-03386-7

BibTeX
@article{Redeker2024,
  author = {Redeker, Imke and Moustakis, Stefan and Tsiami, Styliani and Baraliakos, Xenofon and Kiefer, David and Andreica, Ioana and Buehring, Björn and Braun, Jürgen and Kiltz, Uta},
  title = {A Bayesian model to analyse the association of comorbidities with biosimilar treatment retention in a non-medical switch scenario in patients with inflammatory rheumatic musculoskeletal diseases},
  journal = {Arthritis Research & Therapy},
  year = {2024},
  doi = {10.1186/s13075-024-03386-7}
}
Kostenlos starten →